Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)

0506807 - ÚMG 2020 RIV GB eng J - Journal Article
Jonasova, A. - Neuwirtová, R. - Polackova, H. - Šišková, M. - Stopka, T. - Cmunt, E. - Belickova, M. - Moudrá, Alena - Minařík, L. - Fuchs, O. - Michalová, K. - Zemanová, Z.
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients).
Leukemia Research. Roč. 69, June (2018), s. 12-17. ISSN 0145-2126. E-ISSN 1873-5835
Institutional support: RVO:68378050
Keywords : Myelodysplastic syndromes * Lenalidomide * Del(5q) aberration * Erythropoietin * Prednisone
OECD category: Cell biology
Impact factor: 2.066, year: 2018
Method of publishing: Limited access
https://www.sciencedirect.com/science/article/abs/pii/S0145212618300778?via%3Dihub

Permanent Link: http://hdl.handle.net/11104/0297965